IT1241460B - Formulazioni a cessione protratta di peptidi idrosolubili (caso 600-7110) - Google Patents

Formulazioni a cessione protratta di peptidi idrosolubili (caso 600-7110)

Info

Publication number
IT1241460B
IT1241460B IT48113A IT4811390A IT1241460B IT 1241460 B IT1241460 B IT 1241460B IT 48113 A IT48113 A IT 48113A IT 4811390 A IT4811390 A IT 4811390A IT 1241460 B IT1241460 B IT 1241460B
Authority
IT
Italy
Prior art keywords
protract
sale
formulations
case
water soluble
Prior art date
Application number
IT48113A
Other languages
English (en)
Italian (it)
Other versions
IT9048113A0 (it
IT9048113A1 (it
Inventor
David Bodmer
Jones W Fong
Thomas Kissel
Hawkins V Maulding
Oskar Nagele
Jane E Pearson
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IT9048113A0 publication Critical patent/IT9048113A0/it
Publication of IT9048113A1 publication Critical patent/IT9048113A1/it
Application granted granted Critical
Publication of IT1241460B publication Critical patent/IT1241460B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT48113A 1989-07-07 1990-07-05 Formulazioni a cessione protratta di peptidi idrosolubili (caso 600-7110) IT1241460B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US41134789A 1989-09-22 1989-09-22

Publications (3)

Publication Number Publication Date
IT9048113A0 IT9048113A0 (it) 1990-07-05
IT9048113A1 IT9048113A1 (it) 1992-01-05
IT1241460B true IT1241460B (it) 1994-01-17

Family

ID=27007654

Family Applications (1)

Application Number Title Priority Date Filing Date
IT48113A IT1241460B (it) 1989-07-07 1990-07-05 Formulazioni a cessione protratta di peptidi idrosolubili (caso 600-7110)

Country Status (27)

Country Link
JP (5) JPH0832624B2 (da)
KR (2) KR100303681B1 (da)
AT (1) AT406225B (da)
AU (2) AU641407B2 (da)
BE (1) BE1004486A3 (da)
CA (1) CA2020477C (da)
CH (1) CH685230A5 (da)
CY (1) CY1965A (da)
DE (2) DE4021517B4 (da)
DK (1) DK175849B1 (da)
FI (3) FI108611B (da)
FR (1) FR2649319A1 (da)
GB (2) GB2234896B (da)
GR (1) GR1001121B (da)
HK (2) HK97695A (da)
HU (2) HU221294B1 (da)
IE (2) IE64216B1 (da)
IL (3) IL131881A (da)
IT (1) IT1241460B (da)
LU (1) LU87764A1 (da)
MY (1) MY106722A (da)
NL (1) NL195027C (da)
NO (2) NO302928B1 (da)
NZ (1) NZ234384A (da)
PT (1) PT94628B (da)
SE (1) SE512992C2 (da)
SG (1) SG26416G (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
DE4218510A1 (de) * 1992-06-02 1993-12-09 Pharmatech Gmbh Verfahren zur Herstellung biologisch abbaubarer Polyester
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
CA2123144A1 (en) * 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
KR100354270B1 (ko) 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
CA2432900C (en) 2000-12-21 2007-09-11 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophilic active agents
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
DK1660039T3 (da) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C Forebyggelse af reduktion af polymerens molekylvægt, dannelse af urenheder og gelering i polymersammensætninger
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
EP1719523A4 (en) * 2004-02-26 2009-07-15 Japan Science & Tech Agency MICROPARTICULAR PROTEIN CARBIDE RETARD PREPARATION FOR INJECTION AND METHOD FOR THE PRODUCTION THEREOF
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
ES2492641T3 (es) * 2005-12-22 2014-09-10 Novartis Ag Formulación de liberación sostenida que comprende octreótida y dos o más polímeros de poliláctida-co-glicólido
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US20110003002A1 (en) 2008-01-30 2011-01-06 Holger Petersen Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2621473A2 (en) * 2010-09-30 2013-08-07 Evonik Corporation Method for removing residual organic solvent from microparticles
EP2621474A2 (en) * 2010-09-30 2013-08-07 Evonik Corporation Emulsion method for preparing low residual solvent microparticles
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR102464650B1 (ko) 2016-05-03 2022-11-10 엘에스일렉트릭(주) 배선용 차단기의 한류장치
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH644768A5 (de) * 1977-08-25 1984-08-31 Sandoz Ag Verfahren zur herstellung von mikrokugeln.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
DE19375086I2 (de) * 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (ja) * 1986-03-06 1996-10-02 日本原子力研究所 ポリラクトンからなる徐放性薬物複合体の製造方法
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (da) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
GB2265311B (en) 1994-02-09
IT9048113A0 (it) 1990-07-05
HU903974D0 (en) 1990-11-28
NO983923D0 (no) 1998-08-26
LU87764A1 (fr) 1992-03-11
FI20000059A (fi) 2000-01-12
NL195027B (nl) 2003-08-01
GB2234896A (en) 1991-02-20
DK162590A (da) 1991-01-08
FR2649319A1 (fr) 1991-01-11
NO903001D0 (no) 1990-07-05
KR100303681B1 (ko) 2002-05-16
NL195027C (nl) 2003-12-02
AU641407B2 (en) 1993-09-23
NO983923L (no) 1991-01-08
GB2234896B (en) 1994-01-19
GB9014704D0 (en) 1990-08-22
IT9048113A1 (it) 1992-01-05
CA2020477A1 (en) 1991-01-08
GR1001121B (el) 1993-04-28
NO903001L (no) 1991-01-08
CA2020477C (en) 2000-11-21
PT94628A (pt) 1991-03-20
NL9001537A (nl) 1991-02-01
FI109543B (fi) 2002-08-30
NO302928B1 (no) 1998-05-11
HU211602A9 (en) 1995-12-28
AU2332195A (en) 1995-09-07
CH685230A5 (de) 1995-05-15
IL131880A (en) 2001-12-23
PT94628B (pt) 1997-06-30
NZ234384A (en) 1994-05-26
HK97695A (en) 1995-06-23
DE4021517B4 (de) 2009-04-09
MY106722A (en) 1995-07-31
GB9306204D0 (en) 1993-05-19
FR2649319B1 (da) 1994-12-09
SE9002364L (sv) 1991-01-08
HK197496A (en) 1996-11-08
HUT54037A (en) 1991-01-28
GR900100513A (en) 1991-12-10
KR100442931B1 (ko) 2004-08-02
KR910002430A (ko) 1991-02-25
ATA144090A (de) 1999-08-15
CY1965A (en) 1997-07-04
SG26416G (en) 1995-09-01
HU221294B1 (en) 2002-09-28
IE64411B1 (en) 1995-08-09
SE9002364D0 (sv) 1990-07-05
DE4042752B4 (de) 2009-05-07
JPH07309897A (ja) 1995-11-28
JP2001233897A (ja) 2001-08-28
SE512992C2 (sv) 2000-06-12
DK175849B1 (da) 2005-03-29
IE902435A1 (en) 1991-02-13
FI903429A0 (fi) 1990-07-06
GB2265311A (en) 1993-09-29
DK162590D0 (da) 1990-07-05
FI109334B (fi) 2002-07-15
FI20000060A (fi) 2000-01-12
JP2931773B2 (ja) 1999-08-09
IL94983A0 (en) 1991-06-10
AT406225B (de) 2000-03-27
AU687553B2 (en) 1998-02-26
BE1004486A3 (fr) 1992-12-01
NO320444B1 (no) 2005-12-05
JPH0832624B2 (ja) 1996-03-29
IL94983A (en) 1999-08-17
FI108611B (fi) 2002-02-28
DE4021517A1 (de) 1991-01-17
IE64216B1 (en) 1995-07-26
IL131881A (en) 2001-12-23
JPH07285853A (ja) 1995-10-31
AU5874690A (en) 1991-01-10
JPH08198771A (ja) 1996-08-06
JPH0368511A (ja) 1991-03-25

Similar Documents

Publication Publication Date Title
IT1241460B (it) Formulazioni a cessione protratta di peptidi idrosolubili (caso 600-7110)
DK612689A (da) Peptidderivater
SE8903042L (sv) Pharmaceutical compositions comprising cyklosporins
BR8904045A (pt) Calcado nautico
NO922005D0 (no) Farmasoeytiske preparater
DK163689D0 (da) Peptidderivater
DK492788D0 (da) Peptidsynteseapparat
BR9006934A (pt) Formulacoes aquosas estabilizadas de pequenos peptidios
DK111489D0 (da) Peptider
DK375789A (da) Peptidderivater
PT87350A (pt) Peptide mit phospholipase a2-hemmender wirkung
DK183090A (da) Renininhiberende peptid
DK197989A (da) Peptidanaloger
DK380288D0 (da) Hidtil ukendet peptider
DK301889D0 (da) Peptidderivater
FI930022A0 (fi) Kemiskt foerfarande
KR900700503A (ko) 펩티드
DK177789D0 (da) Peptidderivater
BR8907638A (pt) Preparados de fiacao contendo poliuretano
NO177858C (no) Peptid
FI925259A0 (fi) Kemiskt foerfarande
FI101474B1 (fi) Peptidisynteesi kiinteässä faasissa
KR900701833A (ko) 맥관형성 인자를 조력하는 맥관형성 조력 펩타이드(angiogenic potentiationg peptide)
SE8802429D0 (sv) Peptide analogues
DK154191A (da) Peptidpiller

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970623